State of Wisconsin Investment Board

Allen Control Systems is a defense technology company specializing in the development of autonomous, counter-drone robotic gun systems. The company employs modern engineering methods and technical rigor to enhance the force protection of military and allied forces against sophisticated adversaries. Their innovative solutions aim to fundamentally alter battlefield economics and enable defense forces to maneuver safely and accomplish their missions.

Altriarch is an asset management firm established in 2018 and located in Charleston, South Carolina. The company specializes in alternative investments, focusing on specific market niches to provide asset-based credit solutions for lenders and small businesses. Altriarch aims to deliver strong risk-adjusted returns through its targeted investment strategies.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

FluGen, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007, FluGen specializes in both seasonal and pandemic influenza prevention. The company offers RedeeFlu, a nasal spray vaccine, and utilizes a vaccine-loaded intradermal microneedle delivery device. FluGen's innovative approach includes the use of a live, single replication, intranasally delivered virus with a deleted M2 segment (M2SR), enhancing its ability to prevent the spread of influenza and other respiratory pathogens, including COVID-19.

FluGen, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007, FluGen specializes in both seasonal and pandemic influenza prevention. The company offers RedeeFlu, a nasal spray vaccine, and utilizes a vaccine-loaded intradermal microneedle delivery device. FluGen's innovative approach includes the use of a live, single replication, intranasally delivered virus with a deleted M2 segment (M2SR), enhancing its ability to prevent the spread of influenza and other respiratory pathogens, including COVID-19.

EatStreet, Inc. is an online and mobile food ordering service that connects customers with local restaurants across the United States. Founded in 2009 and headquartered in Madison, Wisconsin, the company caters primarily to college students and young professionals, offering a straightforward and affordable way to order delivery and takeout. The platform serves as a centralized hub, providing users with access to a comprehensive listing of partnered restaurants in their area, enabling quick and convenient food ordering. For restaurant owners, EatStreet offers a one-stop solution for online ordering and marketing, helping them attract new customers and increase sales. Through its web, mobile, and social products, EatStreet enhances the dining experience for consumers while supporting local businesses.

FluGen, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007, FluGen specializes in both seasonal and pandemic influenza prevention. The company offers RedeeFlu, a nasal spray vaccine, and utilizes a vaccine-loaded intradermal microneedle delivery device. FluGen's innovative approach includes the use of a live, single replication, intranasally delivered virus with a deleted M2 segment (M2SR), enhancing its ability to prevent the spread of influenza and other respiratory pathogens, including COVID-19.

NeuWave Medical is a company based in Madison, Wisconsin, that specializes in the development of energy-based minimally invasive medical devices. Founded in 2004 by a team of engineers and physician-scientists, NeuWave Medical is dedicated to addressing clinical needs through innovative solutions that are both effective and minimally invasive. The company aims to create high-quality devices that are preferred by leading physicians and medical centers worldwide, focusing on treating a variety of serious medical conditions.

Rentable is an internet company founded in 2011 and based in Madison, Wisconsin, that focuses on enhancing the apartment rental search experience. The company offers a web-based platform that features localized flat listings, search aids, and map-based searches. Its intuitive user design and robust search functionality allow users to browse apartment listings easily and calculate rent affordability. By leveraging modern technology, Rentable aims to streamline the process of finding suitable rental properties, catering to the needs of rent seekers looking for a more efficient way to search for apartments.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in the development of therapeutic plasmid DNA vaccines, specifically targeting prostate cancer and bone metastases. The company is engaged in creating two distinct vaccines aimed at treating prostate cancer and is also developing a diagnostic test to identify patients who would benefit from these therapies. Madison Vaccines' immune-activating therapies are designed to stimulate the immune system to eradicate residual tumor cells before they progress to overt bone metastases, thus delaying the need for castration therapies and improving the chances of a cure at an early stage of the disease.

Zurex Pharma, Inc. is a pharmaceutical and medical technology company focused on developing and commercializing innovative antimicrobial products aimed at preventing healthcare-associated infections, particularly in surgical site wounds and catheter-related scenarios. The company’s product offerings include ZuraPrep, a pre-surgical skin preparation designed to minimize the risk of surgical site infections; ZurAsept, an antimicrobial and antithrombotic catheter solution that addresses catheter-related bloodstream infections; and ZuraGard, which protects against extra-luminal or exit site infections. Founded in 2008 and headquartered in Middleton, Wisconsin, Zurex Pharma operates as a subsidiary of Ash Access Technology, Inc. The company is dedicated to overcoming scientific and technical challenges in infection prevention, providing healthcare professionals with effective solutions to enhance patient safety.

Datica, founded in 2013 and headquartered in Minneapolis, Minnesota, provides a cloud-based healthcare platform designed to facilitate clinical data exchange for highly regulated industries. The platform enables developers to implement cloud-based user management, secure messaging, and data storage without the complexities of server configuration. By supporting common data structures and mandated health services, Datica allows clients, ranging from mid-to-late-stage startups to Fortune 100 companies, to expedite electronic health record (EHR) integration and ensure compliance with cloud regulations. This approach helps organizations manage sensitive information efficiently and securely in the cloud.

Neurovance, Inc. is a clinical-stage neuroscience company headquartered in Cambridge, Massachusetts, focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, Neurovance has developed centanafadine, a triple reuptake inhibitor that precisely modulates the activity of norepinephrine, dopamine, and serotonin to enhance focus and address symptoms of inattention and disorganization in ADHD patients. As of 2017, Neurovance operates as a subsidiary of Otsuka America, Inc.

EatStreet, Inc. is an online and mobile food ordering service that connects customers with local restaurants across the United States. Founded in 2009 and headquartered in Madison, Wisconsin, the company caters primarily to college students and young professionals, offering a straightforward and affordable way to order delivery and takeout. The platform serves as a centralized hub, providing users with access to a comprehensive listing of partnered restaurants in their area, enabling quick and convenient food ordering. For restaurant owners, EatStreet offers a one-stop solution for online ordering and marketing, helping them attract new customers and increase sales. Through its web, mobile, and social products, EatStreet enhances the dining experience for consumers while supporting local businesses.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in the development of therapeutic plasmid DNA vaccines, specifically targeting prostate cancer and bone metastases. The company is engaged in creating two distinct vaccines aimed at treating prostate cancer and is also developing a diagnostic test to identify patients who would benefit from these therapies. Madison Vaccines' immune-activating therapies are designed to stimulate the immune system to eradicate residual tumor cells before they progress to overt bone metastases, thus delaying the need for castration therapies and improving the chances of a cure at an early stage of the disease.

Datica, founded in 2013 and headquartered in Minneapolis, Minnesota, provides a cloud-based healthcare platform designed to facilitate clinical data exchange for highly regulated industries. The platform enables developers to implement cloud-based user management, secure messaging, and data storage without the complexities of server configuration. By supporting common data structures and mandated health services, Datica allows clients, ranging from mid-to-late-stage startups to Fortune 100 companies, to expedite electronic health record (EHR) integration and ensure compliance with cloud regulations. This approach helps organizations manage sensitive information efficiently and securely in the cloud.

Montage Talent, Inc. specializes in providing live and on-demand voice and video interviewing solutions tailored for large enterprises, healthcare sectors, and staffing and recruitment process outsourcing firms. Established in 2007 and based in Delafield, Wisconsin, the company was previously known as Expressume, Inc. and adopted its current name in 2001. Montage serves a diverse clientele, including numerous Fortune 500 companies, by delivering a modern hiring experience that combines advanced technology with personalized service. As a pioneer in purpose-built video interviewing, Montage's proprietary platform is designed for reliability, scalability, compliance, and security, ensuring it meets enterprise demands. The company emphasizes innovation driven by market needs and data, aiming to enhance the efficiency and predictability of talent acquisition. Additionally, Montage is dedicated to fostering long-term client relationships and providing exceptional support at every stage of the hiring process.

Neurovance, Inc. is a clinical-stage neuroscience company headquartered in Cambridge, Massachusetts, focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, Neurovance has developed centanafadine, a triple reuptake inhibitor that precisely modulates the activity of norepinephrine, dopamine, and serotonin to enhance focus and address symptoms of inattention and disorganization in ADHD patients. As of 2017, Neurovance operates as a subsidiary of Otsuka America, Inc.

NeuWave Medical is a company based in Madison, Wisconsin, that specializes in the development of energy-based minimally invasive medical devices. Founded in 2004 by a team of engineers and physician-scientists, NeuWave Medical is dedicated to addressing clinical needs through innovative solutions that are both effective and minimally invasive. The company aims to create high-quality devices that are preferred by leading physicians and medical centers worldwide, focusing on treating a variety of serious medical conditions.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics targeting central nervous system disorders. Founded in 2009, the company aims to address significant unmet medical needs, particularly in the areas of major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is developing EB-1010, a treatment for depression designed to enhance efficacy while minimizing common side effects associated with standard antidepressants, such as weight gain and sexual dysfunction. Additionally, the company is working on therapies for smoking cessation and impulsivity, targeting patients experiencing withdrawal symptoms and cravings. Through its research and development efforts, Euthymics Bioscience seeks to improve the quality of life for individuals struggling with these challenging conditions.

Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, that specializes in discovering and developing small molecule drugs aimed at addressing unmet medical needs associated with central nervous system disorders. Founded in 2004, the company focuses primarily on serious chronic neurodegenerative diseases, including Alzheimer's disease and schizophrenia. Its drug portfolio features candidates designed for treating cognitive impairments and blocking disease processes in conditions such as Progressive Supranuclear Palsy. Notable projects include MCD-386CR, which targets neurodegenerative diseases, and MCD-386/glycopyrrolate, aimed at preventing Alzheimer's in genetically defined presymptomatic mutation carriers. Additionally, the company is developing MI-08-016/035 for common neurodegenerative diseases and MI-10-022 to address significant unmet needs in schizophrenia.

Caden Biosciences is a life sciences tools and services company focuses on G-protein coupled receptors (GPCRs).

Pinstripe is a top RPO provider with global reach and high customer satisfaction as recognized by HRO Today’s Baker’s Dozen. They serve world-class organizations in financial services, healthcare, pharmaceuticals, technology, advanced manufacturing, biotech, telecommunications and energy.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

ZyStor Therapeutics, Inc. is a privately-held biotechnology company focused on developing enzyme replacement therapies for lysosomal storage diseases. The company specializes in creating innovative replacement technologies that enhance the delivery of therapeutics designed to substitute for missing lysosomal enzymes. These therapies aim to address the needs of patients suffering from genetic disorders characterized by lysosomal storage dysfunction.

Roche NimbleGen is a biotechnology company headquartered in Madison, Wisconsin, that specializes in providing products and services for the life science research market. The company offers a range of solutions including the SeqCap EZ system, which enhances exome enrichment in a single test tube, as well as various library construction kits and reagents. Roche NimbleGen's SeqCap Epi system focuses on DNA methylation assessment, providing tools for single-base resolution analysis. The company utilizes its proprietary Maskless Array Synthesis technology to manufacture high-density DNA microarrays, improving the quality and yield of DNA sequencing data. Additionally, Roche NimbleGen offers software tools such as SignalMap for genomic data visualization and NimbleDesign for library design, alongside comprehensive online technical support. Established in 1999, Roche NimbleGen operates as a subsidiary of Roche Holding AG, emphasizing research and innovation in genomic technologies.

Roche NimbleGen is a biotechnology company headquartered in Madison, Wisconsin, that specializes in providing products and services for the life science research market. The company offers a range of solutions including the SeqCap EZ system, which enhances exome enrichment in a single test tube, as well as various library construction kits and reagents. Roche NimbleGen's SeqCap Epi system focuses on DNA methylation assessment, providing tools for single-base resolution analysis. The company utilizes its proprietary Maskless Array Synthesis technology to manufacture high-density DNA microarrays, improving the quality and yield of DNA sequencing data. Additionally, Roche NimbleGen offers software tools such as SignalMap for genomic data visualization and NimbleDesign for library design, alongside comprehensive online technical support. Established in 1999, Roche NimbleGen operates as a subsidiary of Roche Holding AG, emphasizing research and innovation in genomic technologies.

Cardiac Pathways Corp manufactures minimally-invasive systems used by electrophysiologists to diagnose and treat cardiac tachyarrhythmia (abnormally rapid heart rhythms), which if untreated can cause palpitations, fainting, and sudden cardiac arrest. Cardiac Pathways' products consist principally of systems for performing ablation treatment (a nonsurgical, minimally-invasive technique for neutralizing heart tissue responsible for starting or maintaining a tachyarrhythmia) and for diagnostic mapping (locating the source of the tachyarrhythmia within the heart). Cardiac Pathways was issued a U.S. patent related to its Real-time Position Management Tracking System. Founded in 1991, Cardiac Pathways is based in Sunnyvale, California. As of August 6, 2001, it was acquired by Boston Scientific Corporation.